REFERENCES
- Lind P, Kohlfurst S. Respective roles of thyroglobulin, radioiodine imaging, and positron emission tomography in the assessment of thyroid cancer. Semin Nucl Med 2006;36:194–205.
- Feine U, Lietzenmayer R, Hanke JP, Held J, Wohrle H, Muller-Schauenburg W. Fluorine-18-FDG and iodine-131-iodide uptake in thyroid cancer. J Nucl Med 1996;37:1468–1472.
- Grunwald F, Kalicke T, Feine U, . Fluorine-18 fluorodeoxyglucose positron emission tomography in thyroid cancer: results of a multicentre study. Eur J Nucl Med 1999;26:1547–1552.
- Chung JK, So Y, Lee JS, . Value of FDG PET in papillary thyroid carcinoma with negative 131I whole-body scan. J Nucl Med 1999;40:986–992.
- Castro MR, Bergert ER, Goellner JR, Hay ID, Morris JC. Immunohistochemical analysis of sodium iodide symporter expression in metastatic differentiated thyroid cancer: correlation with radioiodine uptake. J Clin Endocrinol Metab 2001;86:5627–5632.
- Min JJ, Chung JK, Lee YJ, . Relationship between expression of the sodium/iodide symporter and 131I uptake in recurrent lesions of differentiated thyroid carcinoma. Eur J Nucl Med 2001;28:639–645.
- Hooft L, van der Veldt AA, van Diest PJ, . [18F]fluorodeoxyglucose uptake in recurrent thyroid cancer is related to hexokinase i expression in the primary tumor. J Clin Endocrinol Metab 2005;90:328–334.
- Chung JK, Youn HW, Kang JH, Lee HY, Kang KW. Sodium iodide symporter and the radioiodine treatment of thyroid carcinoma. Nucl Med Mol Imaging 2010;44:4–14.
- Mian C, Barollo S, Pennelli G, . Molecular characteristics in papillary thyroid cancers (PTCs) with no 131I uptake. Clin Endocrinol (Oxf) 2008;68:108–116.
- Schonberger J, Ruschoff J, Grimm D, . Glucose transporter 1 gene expression is related to thyroid neoplasms with an unfavorable prognosis: an immunohistochemical study. Thyroid 2002;12:747–754.
- Frilling A, Tecklenborg K, Gorges R, Weber F, Clausen M, Broelsch EC. Preoperative diagnostic value of [(18)F] fluorodeoxyglucose positron emission tomography in patients with radioiodine-negative recurrent well-differentiated thyroid carcinoma. Ann Surg 2001;234:804–811.
- Stokkel MP, Duchateau CS, Dragoiescu C. The value of FDG-PET in the follow-up of differentiated thyroid cancer: a review of the literature. Q J Nucl Med Mol Imaging 2006;50:78–87.
- Hooft L, Hoekstra OS, Deville W, . Diagnostic accuracy of 18F-fluorodeoxyglucose positron emission tomography in the follow-up of papillary or follicular thyroid cancer. J Clin Endocrinol Metab 2001;86:3779–3786.
- Khan N, Oriuchi N, Higuchi T, Endo K. Review of fluorine-18-2-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in the follow-up of medullary and anaplastic thyroid carcinomas. Cancer Control 2005;12:254–260.
- Jung YH, Hah JH, Sung MW, Kim KH, Cho SY, Jeon YK. Reciprocal immunohistochemical expression of sodium/iodide symporter and hexokinase I in primary thyroid tumors with synchronous cervical metastasis. Laryngoscope 2009;119:541–548.
- Brown RS, Leung JY, Fisher SJ, Frey KA, Ethier SP, Wahl RL. Intratumoral distribution of tritiated-FDG in breast carcinoma: correlation between Glut-1 expression and FDG uptake. J Nucl Med 1996;37:1042–1047.
- Ciampi R, Vivaldi A, Romei C, . Expression analysis of facilitative glucose transporters (GLUTs) in human thyroid carcinoma cell lines and primary tumors. Mol Cell Endocrinol 2008;291:57–62.
- Prante O, Maschauer S, Fremont V, . Regulation of uptake of 18F-FDG by a follicular human thyroid cancer cell line with mutation-activated K-ras. J Nucl Med 2009;50:1364–1370.
- Arturi F, Russo D, Giuffrida D, Schlumberger M, Filetti S. Sodium-iodide symporter (NIS) gene expression in lymph-node metastases of papillary thyroid carcinomas. Eur J Endocrinol 2000;143:623–627.
- Park HJ, Kim JY, Park KY, Gong G, Hong SJ, Ahn IM. Expressions of human sodium iodide symporter mRNA in primary and metastatic papillary thyroid carcinomas. Thyroid 2000;10:211–217.
- Sodré AK, Rubio IG, Galrão AL, . Association of low sodium-iodide symporter messenger ribonucleic acid expression in malignant thyroid nodules with increased intracellular protein staining. J Clin Endocrinol Metab 2008;93(10):4141–4145.
- Durante C, Puxeddu E, Ferretti E, . BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism. J Clin Endocrinol Metab 2007;92(7):2840–2843.